A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Full Title

A Phase 2 Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin Lymphoma Back to top


Using a patient’s own cells (special cells called “stem cells”) to help increase blood counts after high doses of chemotherapy is called autologous stem cell transplantation (ASCT). ASCT is a treatment approach used for patients with T-cell non-Hodgkin lymphoma (NHL).

Romidepsin is a drug approved by the U.S. Food and Drug Administration for patients with T-cell NHL whose cancer has returned following therapy. In this study, researchers are seeking to determine if romidepsin is effective for preventing or delaying the return of T-cell NHL after a patient has had high-dose chemotherapy and ASCT. Romidepsin is given intravenously (by vein).

Back to top


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have T-cell NHL and be planning to have high-dose chemotherapy and ASCT.
  • Patients may not have received prior romidepsin therapy nor had ASCT or an allogeneic (donated) transplant.
  • This study is open to patients age 16 to 70.

For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.

Back to top